Core Viewpoint - The deadline for the award application for the Global MedTech Innovation Awards has been extended to June 20, 2025, to allow more time for participants to prepare and submit their materials, aiming to showcase innovations and contributions in the medical technology field [1]. Group 1: Event Overview - The Global MedTech Conference 2024 will take place on July 17, 2025, at the Zhongguancun Exhibition Center in Beijing, with an expected attendance of approximately 500 participants from various sectors including government, hospitals, leading enterprises, startups, investment institutions, and research institutes [5]. - The conference will feature a main stage for showcasing and awarding global medical technology innovations [5]. Group 2: Award Categories - The awards to be presented include: 1. 2025 Global MedTech Innovation Award 2. 2025 Global MedTech Clinical Application Award 3. 2025 Global MedTech Service Contribution Award 4. 2025 Global MedTech Supply Chain Excellence Award 5. 2025 Global MedTech Innovation & Translation Award (Individual) [4][8]. Group 3: Application and Evaluation Process - The application phase is open from now until June 20, 2025, followed by a review phase from June 21 to June 29, with results to be announced between June 30 and July 4, and the awards to be presented on July 17, 2025 [11]. - Participants must meet specific criteria based on their roles, such as medical device companies, clinical doctors, researchers, and service providers, ensuring that the innovations are original, advanced, and have potential for large-scale industrialization [7][10].

数字物理治疗初创公司Hinge Health(HNGE.US)周三将其美股首次公开募股(IPO)定价为每股32美元，处 于预期区间的上限。该公司在此次发行中出售了852万股股票，募资约2.73亿美元。此次发行总量将为 1370万股，其余股份由现有股东出售。 Hinge成立于2014年，将在纽约证券交易所上市，股票代码为"HNGE"。该公司于今年3月提交初步招股 书，并在本月早些时候更新文件，公布28至32美元的预期定价区间。 按IPO价格计算，Hinge Health的估值约为26亿美元，若按完全稀释后股本计算可能更高。这一估值较 2021年10月该公司最后一轮外部融资时的62亿美元私募估值大幅缩水。 这家公司通过软件帮助患者远程治疗急性肌肉骨骼损伤、慢性疼痛及开展术后康复。其联合创始人包括 首席执行官丹尼尔.佩雷斯(Daniel Perez)和执行主席加布里埃尔.梅克伦堡(Gabriel Mecklenburg)，两人都 曾亲身经历过在物理康复上的挣扎。 今年第一季度，Hinge的收入从去年同期的8270万美元增长50%至1.238亿美元，当季实现净利润1710万 美元，而去年同期净亏损为2650万美元。 ...

Core Viewpoint - The event highlighted China's leadership in leveraging digital intelligence to enhance primary healthcare, promoting universal health coverage through innovative technologies and collaborative efforts with global partners [1][4][5]. Group 1: China's Initiatives in Digital Healthcare - China emphasizes the integration of digital technologies in primary healthcare to improve service delivery and accessibility, particularly in rural areas [1][4]. - The Chinese government is committed to a health-first development strategy, focusing on resource allocation and financial investment to enhance healthcare systems [1][3]. - The use of artificial intelligence (AI) and digital infrastructure in healthcare is transforming service delivery, enabling remote consultations and improving diagnostic accuracy [2][4]. Group 2: Global Perspectives on Digital Health - WHO officials recognize China's advancements in digital healthcare as a model for other countries, noting the effective use of AI to empower healthcare workers rather than replace them [2][4]. - The WHO emphasizes the importance of digital innovation in achieving universal health coverage, addressing health inequalities, and enhancing healthcare efficiency [3][5]. - The event served as a platform for sharing insights and promoting effective practices in digital health, aiming to strengthen partnerships and support member countries in developing comprehensive digital health strategies [5][6].

Core Viewpoint - The legal opinion letter confirms that the 2024 annual general meeting of Jiangsu Kangzhong Digital Medical Technology Co., Ltd. was convened and conducted in compliance with relevant laws and regulations, ensuring the legitimacy and effectiveness of the meeting's procedures and voting results [1][17]. Group 1: Meeting Convening and Notification - The board of directors announced the meeting on April 26, 2025, in accordance with the relevant regulations [4]. - The notice for the meeting was sent out 20 days in advance, detailing the time, location, voting methods, and agenda [6]. - The notice and proposals for the meeting complied with the legal requirements [5][6]. Group 2: Attendance and Qualifications - A total of 6 attendees represented 21,624,628 shares, accounting for 24.7446% of the voting shares [7]. - The qualifications of the attendees, including shareholders, directors, supervisors, and legal representatives, were verified and deemed valid [8]. Group 3: Voting Procedures and Results - The voting process was conducted according to legal standards, with no amendments to the proposed resolutions during the meeting [9]. - The meeting approved several resolutions, including the 2024 annual report and financial statements, with voting results indicating significant support [10][11][12]. - Special resolutions were passed with more than two-thirds approval from the attending shareholders [17].

Group 1 - The company announced the resignation of employee representative director Ling Jun due to work adjustments, effective immediately, and he will continue to serve in a research-related role [1][2] - The company held an employee representative meeting on May 16, 2025, to elect Ye Xiaoming as the new employee representative director and member of the audit committee, with a term lasting until the end of the current board's term [2] - The audit committee's composition changed, with Ye Xiaoming replacing Ling Jun as a member, while Guo Jiangguang remains the chairman and Cheng Xingbao continues as a member [2] Group 2 - Ye Xiaoming, born in 1985, has a background in IT engineering and has held various positions within the company, including Vice President of Sales, and is now appointed as the employee representative director and audit committee member [2]

Core Viewpoint - The medical technology industry is at a crossroads of breakthrough and reconstruction, with advancements in AI-assisted diagnosis, high-end smart medical devices, innovative medical materials, and regenerative medicine reshaping disease discovery, treatment, and management [1]. Group 1: Conference Overview - The Second Global MedTech Conference will be held on July 17, 2025, at the Zhongguancun Exhibition Center in Beijing, aiming to promote the collaborative development of the global medical technology industry chain, innovation chain, and clinical applications [1][4]. - The first conference, Global MedTech Conference 2024, was organized by Siyu [2]. Group 2: Awards and Recognition - The conference will present several awards to recognize breakthroughs in medical technology, including the 2025 Global MedTech Innovation Award and the 2025 Global MedTech Clinical Application Award [3][7]. - The awards aim to honor cutting-edge technological advancements, successful results transformation, and outstanding services in the medical technology field [3]. Group 3: Conference Agenda - Proposed agenda topics include analysis of global medical technology development trends and policy environments, research and transformation paths for imaging platforms, new consumables, brain-computer interfaces, interventional devices, and diagnostic equipment [5]. - Other topics will cover the intersection of engineering and medicine, AI-assisted diagnosis, digital therapy breakthroughs, and capital market interests in technology directions and company profiles [5]. Group 4: Participation and Submission Guidelines - The awards are open to medical device and digital medical technology companies with innovative products or platform technologies that demonstrate originality, advancement, and scalability potential [6]. - Submission for the awards is open until May 31, 2025, with a review phase from June 1 to June 15, 2025, and results to be announced between June 16 and June 22, 2025 [10].

Core Viewpoint - The "Four Major Chronic Diseases Major Project" aims to establish a comprehensive mechanism for the prevention and treatment of chronic diseases in China by 2030, focusing on collaboration across various sectors to enhance the accessibility and efficiency of healthcare solutions [1][2]. Group 1: Project Overview - The project is led by Tianjin University of Traditional Chinese Medicine and involves multiple high-level universities, medical institutions, and AI healthcare companies [1][2]. - It aims to create a low-cost, high-efficiency, and widely accessible digital health model for chronic disease prevention and management [2][4]. Group 2: Objectives and Implementation - The project has four specific goals: to build a promotion mechanism for chronic disease prevention technologies, establish a digital platform, develop comprehensive treatment plans for major diseases, and create a new paradigm for integrated health management [2][6]. - It will utilize a collaborative model that integrates government, industry, research, and education to address existing challenges in chronic disease management [2][4]. Group 3: Expert Insights - Academicians emphasized the importance of a comprehensive approach that covers the entire population and disease cycle, aiming for a high-efficiency and low-cost prevention system [4]. - The project is expected to provide a Chinese solution to global health challenges by promoting a combination of traditional and modern medical practices [4][6]. Group 4: Technological Integration - The project will leverage AI and digital technologies to enhance the efficiency and coverage of chronic disease prevention strategies [6][11]. - A digital health community model has been successfully implemented in Tianjin, demonstrating improvements in health indicators and reductions in healthcare costs [7][11]. Group 5: Future Directions - The research outcomes will be implemented across 60 regional urban and rural healthcare networks, promoting the integration of digital solutions in chronic disease management [11][12]. - The project will focus on creating a decision-support system for chronic disease prevention and treatment, utilizing AI and digital platforms for widespread application [11].

Core Viewpoint - The medical technology industry is at a crossroads of breakthrough and reconstruction, with advancements in AI-assisted diagnosis, high-end intelligent diagnostic equipment, innovative medical materials, and regenerative medicine reshaping disease discovery, treatment, and management [1] Group 1: Conference Overview - The Second Global MedTech Conference will be held on July 17, 2025, at the Zhongguancun Exhibition Center in Beijing, aiming to promote the collaborative development of the global medical technology industry chain, innovation chain, and clinical application [1][4] - The first conference, Global MedTech Conference 2024, was organized by Siyu [2] Group 2: Awards and Recognition - The conference will present several awards to recognize breakthroughs in medical technology, including the 2025 Global MedTech Innovation Award and the 2025 Global MedTech Clinical Application Award [3][7] - The awards aim to honor innovative products or platform technologies with originality, advancement, and potential for large-scale industrialization [6] Group 3: Conference Agenda - Proposed agenda topics include analysis of global medical technology development trends and policy environments, research and transformation paths for imaging platforms, new consumables, brain-computer interfaces, interventional devices, and diagnostic equipment [5] - Other topics will cover AI-assisted diagnosis, digital therapy breakthroughs, and insights into technology directions and enterprise profiles that attract domestic and foreign capital [5] Group 4: Participation and Submission Process - Companies interested in participating in the awards must fill out a designated form and submit relevant documents by May 31, 2025 [9][10] - The evaluation phase will occur from June 1 to June 15, 2025, with results announced between June 16 and June 22, 2025 [10]

Core Viewpoint - The eighth health ministerial meeting of the Shanghai Cooperation Organization (SCO) emphasized the importance of digital health as a key driver for regional health cooperation and economic transformation, with a focus on emergency medicine, primary health care, digital health, and traditional medicine [1][2]. Group 1: Digital Health Initiatives - The meeting highlighted the need for member countries to strengthen cooperation in the application of digital health technologies to innovate and develop health services [2]. - The SCO Secretary-General pointed out the organization's commitment to the digital transformation of healthcare, particularly in telemedicine, supported by the "Telemedicine Cooperation Concept" established at the 2022 Samarkand Summit [1][2]. - The digital health system in Xi'an demonstrated the effectiveness of digital healthcare, allowing for real-time uploads and diagnostics, showcasing the benefits of digital health advancements [2]. Group 2: International Collaboration and Standards - The World Health Organization (WHO) is working with countries to develop digital health strategies that enhance the accessibility and quality of healthcare services through telemedicine and electronic health records [3]. - There is a call for China to collaborate with other countries in developing new medical technologies, including artificial intelligence, and to help establish international standards in the digital health sector [3]. - The successful hosting of the health ministerial meeting lays a solid foundation for the upcoming SCO summit in Tianjin, China, in 2025, furthering health cooperation among member states [3].

2025年3月28日， 清华大学将与中国工程院联合主办 "2025世界数字健康论坛" ，论坛将聚焦 "数智创新·激发健康医疗新格局" 主题，探讨如何借助数字化智能化技 术释放医疗卫生潜力，培养数智健康跨界人才，培育壮大新业态新模式，加速数字健康产业化进程，提升健康治理水平，为构建健康医疗领域新质生产力体系、推 动经济社会高质量发展提供新动能。 思宇MedTech作为"2025世界数字健康论坛"宣传单位 ，诚挚邀请各行业领军企业、创新型企业及有关机构参与本次论坛，共同探讨交流健康医疗行业数字化、智能 化转型未来方向，助力健康中国建设和全球健康事业发展。对贵公司的支持表示由衷的感谢！ 后附2024年会议总结，供感兴趣的企业参考。 一、会议时间： 2025年3月28日星期五 8:30-18:00 权威机构主办： 清华大学、中国工程院；在国家级会议"中关村论坛"上举行。 重量级嘉宾： （部分去年参会嘉宾；排名不分先后）（今年更是盛况空前） 王 辰 中国工程院副院长，中国工程院院士 董家鸿（清华大学临床医学院院长，中国工程院院士） 张伯礼（中国工程院医药卫生学部主任、中国工程院院士、国医大师） 尤 政 华中科技大学校长 ...